CD274 and hepatocellular carcinoma: These results illustrated that the ODN1585 and anti-PD-1 antibody or anti-PD-L1 antibody combination indeed improved antitumor activity in the HCC mouse subcutaneous and orthotopic tumor model, which was consistent with animal research and clinical trial results 29, 30, 42.